Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 137

Results For "MIT"

5105 News Found

Briefs: Jagsonpal Pharmaceuticals, Dr. Reddy’s Laboratories and Akums Drugs and Pharmaceuticals
News | November 20, 2024

Briefs: Jagsonpal Pharmaceuticals, Dr. Reddy’s Laboratories and Akums Drugs and Pharmaceuticals

Jagsonpal Pharmaceuticals has received full consideration of Rs. 41 crore towards the sale of the facility and will now be proceeding with registration formalities


Lupin receives USFDA approval for mixed salts of a single-entity amphetamine ER capsules
Drug Approval | November 20, 2024

Lupin receives USFDA approval for mixed salts of a single-entity amphetamine ER capsules

The product will be manufactured at Lupin’s Somerset facility in the US


Lupin launches Bumetanide Injection USP in US
News | November 20, 2024

Lupin launches Bumetanide Injection USP in US

Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US


Indegene announces new Center in Hyderabad
Digitisation | November 20, 2024

Indegene announces new Center in Hyderabad

With 6 operation hubs and 18 offices across North America, Europe, and Asia, Indegene’s client base includes the world’s top 20 biopharma companies


CPHI India reports surge in exhibitor numbers
News | November 20, 2024

CPHI India reports surge in exhibitor numbers

Modernization and supply chain diversity drive new growth


DKSH and Abcam join forces to advance life science research in Vietnam
Supply Chain | November 19, 2024

DKSH and Abcam join forces to advance life science research in Vietnam

This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market


Shilpa Pharma Lifesciences received CEP from EDQM for API, Octreotide
Drug Approval | November 19, 2024

Shilpa Pharma Lifesciences received CEP from EDQM for API, Octreotide

Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis


Tagrisso recommended for approval in the EU for unresectable EGFR-mutated lung cancer
Drug Approval | November 19, 2024

Tagrisso recommended for approval in the EU for unresectable EGFR-mutated lung cancer

Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years